Review Article

Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis

Yue Zhang,1 Yanrong Suo,2 Lin Yang,3 Xiaolu Zhang,1 Qun Yu,1 Miao Zeng,1 Wenlan Zhang,1 Xijuan Jiang,1 and Yijing Wang3

1School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
2Traditional Chinese Medicine Department, Ganzhou People’s Hospital, Ganzhou, China
3School of Nursing, Tianjin University of Traditional Chinese Medicine, Tianjin, China

Correspondence should be addressed to Xijuan Jiang; jxj2668@tjutcm.edu.cn and Yijing Wang; wangyj1986@tjutcm.edu.cn

Received 1 February 2022; Revised 30 March 2022; Accepted 7 April 2022; Published 26 April 2022

Academic Editor: Costantino Mancusi

Copyright © 2022 Yue Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. We aimed to investigate the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor on blood lipid levels in patients with high and very-high cardiovascular risk.

Design. 14 trials (n = 52,586 patients) comparing treatment with or without PCSK9 inhibitors were retrieved from PubMed and Embase updated to 1st Jun 2021. The data quality of included studies was assessed by two independent researchers using the Cochrane systematic review method. All-cause mortality, cardiovascular mortality, and changes in serum low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), apo-lipoprotein B (ApoB), lipoprotein (a) (LP (a)), non-high-density lipoprotein cholesterol (non-HDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein A1 (ApoA1) from baseline were analyzed using Rev Man 5.1.0 software.

Results. Compared with treatments without PCSK9 inhibitor, addition of PCSK9 inhibitors (evolocumab and alirocumab) had obvious decreasing effects on the levels of LDL-C [MD = −46.86, 95% CI (−54.99 to −38.72), P < 0.00001], TC [MD = −31.92, 95% CI (−39.47 to −24.38), P < 0.00001], TG [MD = −8.13, 95% CI (−10.48 to −5.79), P < 0.00001], LP (a) [MD = −26.69, 95% CI (−37.93 to −15.44), P < 0.00001], non-HDL-C [MD = −42.86, 95% CI (−45.81 to −39.92), P < 0.00001], and ApoB [MD = −38.44, 95% CI (−42.23 to −34.65), P < 0.00001] in high CVD risk patients. Conversely, changes of HDL-C [MD = 6.27, CI (5.17 to 7.36), P < 0.00001] and ApoA1 [MD = 4.33, 95% CI (3.53 to 5.13), P < 0.00001] from baseline were significantly more in high cardiovascular disease risk patients who received PCSK9 inhibitor treatment. Conclusion. Addition of PCSK9 inhibitors to standard therapy resulted in definite improvement in blood lipid levels compared with therapies that did not include them.

1. Introduction

Cardiovascular disease (CVD) remains the highest cause of morbidity and mortality worldwide [1]. A significant portion of CVD can be attributed to underlying coronary artery disease (CAD) with atherosclerosis, termed as atherosclerotic cardiovascular disease (ASCVD) [2, 3]. The important risk factor of ASCVD is dyslipidemia that includes hyper-triglycerideremia, hypercholesterolemia, higher low-density lipoproteinemia (LDL), and mixed hyperlipidemia [4]. Meanwhile, non-high-density lipoprotein cholesterol (non-HDL-C) [5], such as lipoprotein (a) (LP (a)) and very low-density lipoprotein cholesterol (VLDL-C), is also involved in the progression of ASCVD [6, 7]. Thus, management of dyslipidemia is a key component of primary and secondary risk-reduction strategies.

The previous guidelines classified CVD risk into four categories, low, moderate, high, and very-high risk, based on systematic coronary risk estimation (SCORE) in 10-year risk of deadly CVD [8–10]. The patients with high and very-high CVD risk are considered to be at risk for more severe clinical outcomes and higher recurrence rates [11–13], suggesting that we should pay sufficient attention to patients at high and very-high risk of CVD to prevent serious clinical outcomes.
It is shown that lipid-lowering medicines are benefit to ASCVD [14, 15]. Statin, an HMG-CoA reductase inhibitor, is the most effective therapeutic intervention to lower low-density lipoprotein cholesterol (LDL-C) [16]. However, patients with high CVD risk did not achieve sufficient statins treatment because of their side-effects [17]. The HPS2-THRIVE study showed that the incidence of adverse reactions was higher in Chinese population than in Europe and United States for the same dose of statin [18]. Furthermore, a doubling dose of statin was associated with greater lowering of LDL-C only by 4% to 6% and non-HDL-C by 3% to 6% [19]. The LDL-C levels of many high risk and very high-risk CVD patients still did not up to scratch after maximal tolerated statin therapy. Due to the existence of these conditions, intensive lipid-lowering therapy by nonstatin drugs or statins combined with nonstatin drugs may be an important option for patients with high CVD risk and very-high CVD risk.

PCSK9 is synthesized by hepatic inactive proprotein convertase and circulates either freely or bound to atherogenic lipoproteins, such as Lp (a) and LDL [20]. When PCSK9 binds directly to LDL receptor (LDLR), the LDL-C level in the circulation is elevated via degrading LDLR in the hepatocyte cell membrane [21] (Figure 1). Since the discovery of PCSK9, researchers gradually pay attention to inhibit the activity of this protein. The two monoclonal antibodies targeting PCSK9, alirocumab and evolocumab, have been approved in several countries around the world [20]. Data derived from the FOURIER trial on evolocumab and ODYSSEY OUTCOMES on alirocumab have indicated a clear clinical benefit in subjects at high CVD risk. Additionally, 2019 ESC/EAS guideline suggests that the treatments using PCSK9 inhibitors alone or in combination with statins clearly reduce the risk of recurrent ASCVD events in high-risk patients [8]. However, the benefit and safety of PCSK9 inhibitor administration on overall lipid levels of high and very-high cardiovascular risk patients is to be explored. Therefore, we performed a meta-analysis of randomized controlled trials (RCTs) to assess the clinical evidence for PCSK9 inhibitors.

2. Methods

This meta-analysis was conducted in accordance with the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) statement (Supplementary Table S1) [22].

2.1. Research Strategy. Articles from PubMed/Medline, Embase databases, CENTRAL (Cochrane Central Register of Controlled Trials), and ClinicalTrials.gov were screened and selected up to June 2021. Additional searches were performed by scrutinizing relevant reviews and meta-analyses. The following keywords were used “PCSK9 inhibitor,” “cardiovascular disease,” “high risk,” and “lipid-lowering.” Trials were limited to RCTs and English literature (the search strategy of PubMed database is shown in Supplementary Table S2).

2.2. Literature Inclusion Criteria

2.2.1. Research Design. RCTs were selected regardless of publication restrictions. Due to the different standards for high risk and very-high risk patients in the official guidelines each year, the inclusion and exclusion criteria for high risk and very-high risk patients in this study followed the guideline criteria for the year in which the trials were conducted.

2.2.2. Research Subjects. The study included patients who had high and very-high risk of cardiovascular disease (P).

2.2.3. Intervention. The control group received standard therapy with statins alone or ezetimibe alone or a combination therapy of statins and ezetimibe (C), while the experimental group received PCSK9 inhibitor besides the treatments applied in control group therapy (I).

2.2.4. Outcome Indicators. Outcome indicators included all-cause mortality and cardiovascular mortality, percentage of decrease from baseline of serum LDL-C, total cholesterol (TC), triglyceride (TG), apolipoprotein B (ApoB), LP (a), non-HDL-C, high-density lipoprotein cholesterol (HDL-C), and apolipoprotein A1(ApoA1) (O).

2.3. Document Exclusion Criteria. The following were excluded: (1) duplicate articles, (2) case reports, (3) animal experimental studies, (4) review and observational studies, (5) trials with no relevant population, and (6) trials with no relevant outcome.

2.4. Quality Assessment and Data Extraction. The included studies were subject to be appraised against the criteria for quality assessment recommended by the Cochrane systematic review [23], which consists of six domains: (1) random assignment method, (2) hidden assignment, (3) the use of blind method, (4) data completeness, (5) selective study results, and (6) biased presence. “Low or high risk” means a low or high risk of trial bias, and “unclear risk” means that sufficient information from the literature could not be obtained for risk of bias assessment. Quality assessment was performed by two independent investigators. Disagreements were solved by discussion or third-party judgement.

2.5. Statistical Analysis. Data were analyzed by Rev Man 5.1.0 software and Stata 16.0. Count data was assessed with risk ratio (RR) to determine the effect size, while mean difference (MD) was used to analyze the continuous data for determining the variance values and displaying the 95% confidence interval (CI95) of the P value and I² statistic of the heterogeneity test results shown in forest plot were used to ascertain whether the included studies were heterogeneous. If the heterogeneity was insignificant (P ≥ 0.1, I² ≤ 50%), the fixed effects model was used to combine effect sizes; if the
heterogeneity was significant ($P < 0.1$, $I^2 > 50\%$), effect sizes were combined using a random-effects model. We used sensitivity analysis to assess the stability of our results. Publication bias was examined visually and additional checks were performed by Begg’s test.

2.6. Patient and Public Involvement Statement. This is a meta-analysis study with no patients involved.

3. Results

3.1. Literature Screening. At the beginning, 492 articles were included. Then, 51 duplicate articles were removed and another 338 articles were excluded by comparing their title and abstract against exclusion criteria. By then, 103 English articles were remained, whose full text were read and screened against exclusion and inclusion criteria. Finally, 14 trials with 52,586 patients were included in the meta-analysis. The process of literature screening was shown in Supplementary Figure S1.

3.2. Literature Quality Evaluation. A total of 52,586 experimental patients were included in this meta-analysis, with an average age of 61 years. Female patients accounted for 26.3%, and the average duration of treatment with PCSK9 inhibitor was 24 weeks. More general information and inclusion criteria of 14 trials were, respectively, shown in Table 1 and Supplementary Table S3, and the literature quality evaluations were presented in Supplementary Figures S2 and S3.

3.3. Meta-Analysis Outcome

3.3.1. All-Cause Mortality. All of 14 studies ($n = 51,080$ patients) had demonstrated the clinical security of treatments with PCSK9 inhibitors. There was no significant heterogeneity ($I^2 = 41\%$, $P = 0.10$) in the all-cause mortality of whole included patients, so meta-analysis was conducted using fixed effect model. The experimental group did not show significant change in all-cause mortality compared with that in control group [$RR = 0.93$, 95% CI (0.85, 1.02), $P = 0.14$], as shown in Figure 2.

3.3.2. Cardiovascular Mortality. There was no significant heterogeneity ($I^2 = 33\%$, $P = 0.20$) in the cardiovascular mortality of 49,860 patients, so meta-analysis was conducted using fixed effect model. The experimental group did not show significant change in cardiovascular mortality compared with that in control group [$RR = 0.95$, 95% CI (0.84, 1.07), $P = 0.36$], as shown in Figure 3.

3.3.3. LDL-C Level. Nineteen studies include serum LDL-C levels as a parameter to examine PCSK9 inhibitor interventions. In total, 6,230 patients were included, and the heterogeneity was significant ($P < 0.00001$, $I^2 = 100\%$), so random-effects model was applied. Meta-analysis showed...
that the reduction of serum LDL-C level from baseline was significantly greater in experimental group of patients with high and very-high CVD risk than those in control group \(Z = 11.29, \text{ MD} = -46.86, 95\% \text{ CI} (-54.99 \text{ to} -38.72), P < 0.00001\), as shown in Figure 4.

### 3.3.4. TC Level

As shown in Figure 5, nine studies with 27,805 patients were analyzed the effect of PCSK9 inhibitor on TC level, and the heterogeneity was significant \(P < 0.00001, I^2 = 100\%\). Data showed that the serum TC level from baseline in high and very-high CVD risk patients
was reduced even more in experimental group than in control group \( Z = 8.29, \text{MD} = -31.92, 95\% \text{ CI} (-39.47 \text{ to } -24.38), P < 0.00001 \).

### 3.3.5. TG and LP(a) Level.
Seventeen studies investigated serum TG and LP(a) levels in 30,604 patients to assess the effect of PCSK9 inhibitors on intervention for high- and very high-risk CVD. Heterogeneity was significant \( (P < 0.00001, I^2 = 100\%) \), so a random-effects model was used. The results showed that the reduction in serum TG and LP(a) levels from baseline were markedly greater in experimental group than in control group \( I^2 = 41\% \), as shown in Figure 3.

### 3.3.6. Non-HDL-C and ApoB Levels.
Twenty studies on serum non-HDL-C and ApoB levels were included to evaluate the effect of PCSK9 inhibitors, as shown in Figures 8 and 9. A total of 31,471 patients were included, with significant heterogeneity \( (P < 0.00001, I^2 = 100\%) \), so a random-effects model was used. The results suggested that the decreases in serum non-HDL-C and ApoB levels from baseline were substantially greater in experimental group than in control group \( I^2 = 41\% \), as shown in Figures 6 and 7.

### 3.3.7. HDL-C Level.
Twenty studies included serum HDL-C level to assess the effect of PCSK9 inhibitor interventions. Overall, 31,471 patients were included, and the heterogeneity was significant \( (P < 0.00001, I^2 = 100\%) \), so random-effects model was used. Meta-analysis showed that the raise of serum HDL-C level from baseline was significantly greater in experimental group than those in control group \( I^2 = 41\% \), as shown in Figure 10.

### 3.3.8. ApoA1 Level.
A total of nine studies (29,909 patients) reported serum ApoA1 level to assess the effect of PCSK9 inhibitors on intervention for high- and very high-risk CVD. Heterogeneity was significant \( (P < 0.00001, I^2 = 100\%) \), so a random-effects model was used. The results suggested that the increases in serum ApoA1 levels from baseline were substantially greater in experimental group than in control group \( I^2 = 41\% \), as shown in Figures 11 and 12.
Heterogeneity: Tau^2 = 132.72; Chi^2 = 86115.85, df = 8 (P < 0.00001);

| Study or Subgroup          | experimental Mean SD Total | control Mean SD Total | Weight (%) | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|----------------------------|-----------------------------|-----------------------|------------|-----------------------------------|-----------------------------------|
| BERSON-I                   | −73 2.3 150 12 3.2 74      | 5.3 −85.00 [−85.82, −84.18] |
| BERSON-II                  | −65.4 1.9 152 9.5 2.7 75   | 5.3 −74.90 [−75.58, −74.22] |
| ODYSSEY COMBO I            | −47.9 29.1 205 −2.5 24.9 106 | 5.1 −45.40 [−51.59, −39.21] |
| ODYSSEY COMBO II           | −51.2 1.3 467 −21.8 1.8 240 | 5.3 −29.40 [−29.66, −29.14] |
| ODYSSEY EAST               | −56 1.5 403 −20.3 2 208    | 5.3 −35.70 [−36.01, −35.39] |
| ODYSSEY HoFH               | −62.8 14 45 8.9 19 24      | 5.0 −71.70 [−80.33, −63.07] |
| ODYSSEY JAPAN              | −62.5 1.3 144 1.6 1.8 72   | 5.3 −64.10 [−64.57, −63.63] |
| ODYSSEY KT                 | −57.1 3 97 6.3 2.9 102    | 5.3 −63.40 [−64.22, −62.58] |
| ODYSSEY LONG TERM          | −61 0.7 1530 0.8 1 780    | 5.3 −61.80 [−61.88, −61.72] |
| ODYSSEY OPTIONS I          | −50.5 3.2 46 −14.5 3.2 47  | 5.3 −36.00 [−37.30, −34.70] |
| ODYSSEY OPTIONS I-2        | −48.4 3.8 55 −8.5 3.9 53   | 5.3 −39.90 [−41.35, −38.45] |
| ODYSSEY OPTIONS I-3        | −50.5 3.2 46 −29.7 3.2 46  | 5.3 −20.80 [−22.11, −19.49] |
| ODYSSEY OPTIONS I-4        | −48.4 3.8 55 −22.6 3.9 53   | 5.3 −25.80 [−27.25, −24.35] |
| ODYSSEY OPTIONS II         | −32.3 5.2 53 −22.1 5.3 52   | 5.3 −10.20 [−12.21, −8.19] |
| ODYSSEY OPTIONS II-2       | −49.6 4.1 48 −17.1 4.1 48   | 5.3 −32.50 [−34.14, −30.86] |
| ODYSSEY OPTIONS II-3       | −32.3 5.2 53 −19.3 5.4 50   | 5.3 −13.00 [−15.05, −10.95] |
| ODYSSEY OPTIONS II-4       | −49.6 4.1 48 −17.4 4.2 47   | 5.3 −32.20 [−33.87, −30.53] |
| YUKAWA-1                   | −70.1 0.9 146 −1.9 1.5 73   | 5.3 −68.20 [−68.57, −67.83] |
| YUKAWA-2                   | −70 1.4 224 11.3 3.2 113    | 5.3 −81.30 [−81.92, −80.68] |

Total (95% CI) 3967 2263 100.0% −46.86 [−54.99, −38.72]

Heterogeneity: Tau^2 = 325.49; Chi^2 = 104962.88, df = 18 (P < 0.00001); I^2 = 100%

Test for overall effect: Z = 11.29 (P < 0.00001)

Figure 4: Comparison of the reduction of serum LDL-C (%) from baseline between control group and experimental group.

Study or Subgroup Mean SD Total Mean SD Total Weight (%) Mean Difference IV, Random, 95% CI Mean Difference IV, Random, 95% CI

| Study or Subgroup          | experimental Mean SD Total | control Mean SD Total | Weight (%) | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|----------------------------|-----------------------------|-----------------------|------------|-----------------------------------|-----------------------------------|
| BERSON-I                   | −40.4 1.5 150 6.9 2.1 75  | 11.2 −47.30 [−47.83, −46.77] |
| BERSON-II                  | −36.7 1.2 152 5 1.7 74   | 11.2 −41.70 [−42.13, −41.27] |
| FOURIER                    | −35.5 0.408 12645 0.374 12596 | 11.2 −35.50 [−35.51, −35.49] |
| ODYSSEY COMBO I            | −27.7 18.4 205 −3.1 18.7 106 | 10.8 −24.60 [−28.96, −20.24] |
| ODYSSEY COMBO II           | −29.3 0.9 467 −14.6 12 240 | 11.2 −14.70 [−14.87, −14.53] |
| ODYSSEY EAST               | −33.9 0.9 403 −13.8 12 208 | 11.2 −20.10 [−20.29, −19.91] |
| ODYSSEY HoFH               | −19.8 3.7 45 6.6 5 24    | 11.1 −26.40 [−28.67, −24.13] |
| ODYSSEY JAPAN              | −39.5 0.9 144 2 1.3 72   | 11.2 −41.50 [−41.83, −41.17] |
| ODYSSEY KT                 | −31.2 1.8 97 4 1.8 102   | 11.2 −35.20 [−37.50, −34.70] |

Total (95% CI) 14308 13497 100.0% −31.92 [−39.47, −24.38]

Heterogeneity: Tau^2 = 132.72; Chi^2 = 86115.85, df = 8 (P < 0.00001); I^2 = 100%

Test for overall effect: Z = 8.29 (P < 0.00001)

Figure 5: Comparison of the reduction of serum TC (%) from baseline between control group and experimental group.

inhibitors. Data heterogeneity was significant (P < 0.00001, I^2 = 100%), so a random-effects model was used. Meta-analysis showed that the increase in serum ApoA1 level from baseline was considerably greater in high CVD patients with alirocumab or evolocumab [Z = 10.57, MD = 4.33, 95% CI (3.53 to 5.13), P < 0.00001], as shown in Figure 11.

3.3.9. Publication Bias. Publication bias was showed in Supplementary Table S4 and Supplementary Figures S4 and S5. No publication bias was identified by visually inspected the funnel plot or by Begg’s test in analyzing the outcomes of all-cause death, cardiovascular mortality, LDL-C, TC, TG, LP (a), non-HDL-C, ApoB, HDL-C, and ApoA1.
### Figure 6: Comparison of the reduction of serum TG (%) from baseline between control group and experimental group.

| Study or Subgroup | experimental | control | Weight (%) | Mean Difference | Mean Difference |
|-------------------|--------------|---------|------------|-----------------|----------------|
|                   | Mean  | SD   | Total   | Mean  | SD   | Total   | IV, Random, 95% CI | IV, Random, 95% CI |
| BERSON-I          | −5.4  | 4.1  | 150     | 3.6   | 5.6  | 75      | 5.9 −9.00 [−10.43, −7.57] |
| BERSON-II         | −11.1 | 2.6  | 152     | 7.1   | 3.7  | 74      | 6.0 −18.20 [−19.14, −17.26] |
| FOURIER           | −16.2 | 0.617| 12645   | −0.7  | 0.8115| 12956   | 6.0 −15.50 [−15.52, −15.48] |
| ODYSSEY COMBO II | −13   | 1.5  | 467     | −12.8 | 2    | 240     | 6.0 −0.20 [−0.49, 0.09] |
| ODYSSEY EAST      | −14.5 | 1.3  | 403     | −14.4 | 1.9  | 208     | 6.0 −0.10 [−0.39, 0.19] |
| ODYSSEY HoFH      | −7.4  | 4.2  | 45      | 3.9   | 5.7  | 24      | 5.6 −11.30 [−13.89, −8.71] |
| ODYSSEY JAPAN     | −15.3 | 2.6  | 144     | 6.7   | 3.7  | 72      | 5.9 −22.00 [−22.95, −21.05] |
| ODYSSEY KT        | −8.1  | 3.2  | 97      | −3.6  | 3.1  | 102     | 6.0 −4.50 [−5.38, −3.62] |
| ODYSSEY LONG TERM | −15.6 | 0.8  | 1530    | 1.8   | 1.2  | 780     | 6.0 −17.40 [−17.49, −17.31] |
| ODYSSEY OPTIONS I | −19.1 | 4.1  | 46      | −7.3  | 4.1  | 47      | 5.8 −11.80 [−13.47, −10.13] |
| ODYSSEY OPTIONS I-I | −12  | 3.7  | 55      | −6.7  | 3.7  | 53      | 5.9 −5.30 [−6.70, −3.90] |
| ODYSSEY OPTIONS I-3 | −19.1 | 4.1  | 46      | −13.9 | 4.1  | 46      | 5.8 −5.20 [−6.88, −3.52] |
| ODYSSEY OPTIONS I-4 | −12  | 3.7  | 55      | −3.3  | 4.1  | 53      | 5.9 −8.70 [−10.17, −7.23] |
| ODYSSEY OPTIONS II | −8.7  | 4.5  | 53      | −9.9  | 4.1  | 52      | 5.8 1.20 [−0.45, 2.85] |
| ODYSSEY OPTIONS II-2 | −11.2 | 4.6  | 48      | −1.8  | 4.5  | 48      | 5.8 −9.40 [−11.22, −7.58] |
| ODYSSEY OPTIONS II-3 | −8.7  | 4.5  | 53      | −11.1 | 4.3  | 50      | 5.8 2.40 [0.70, 4.10] |
| ODYSSEY OPTIONS II-4 | −11.2 | 4.6  | 48      | −8.3  | 4.8  | 47      | 5.8 −2.90 [−4.79, −1.01] |

Total (95% CI): 16037 14567 100.0% −8.13 [−10.48, −5.79]

Heterogeneity: Tau² = 23.84; Chi² = 25844.00, df = 16 (P < 0.00001); I² = 100%
Test for overall effect: Z = 6.80 (P < 0.00001)

Favours [experimental] Favours [control]

### Figure 7: Comparison of the reduction of serum Lp (a) (%) from baseline between control group and experimental group.

| Study or Subgroup | experimental | control | Weight (%) | Mean Difference | Mean Difference |
|-------------------|--------------|---------|------------|-----------------|----------------|
|                   | Mean  | SD   | Total   | Mean  | SD   | Total   | IV, Random, 95% CI | IV, Random, 95% CI |
| BERSON-I          | −48.3 | 2.7  | 150     | 2.2   | 3.7  | 75      | 6.1 −50.50 [−51.44, −49.56] |
| BERSON-II         | −42.1 | 2.6  | 152     | 0.9   | 3.6  | 74      | 6.1 −43.00 [−43.92, −42.08] |
| FOURIER           | −26.9 | 0.7875| 12645   | 0.139 | 12596| 6.3 −26.90 [−26.91, −26.89] |
| ODYSSEY COMBO II  | −27.8 | 1.4  | 467     | −6.1  | 2    | 240     | 6.3 −21.70 [−21.98, −21.42] |
| ODYSSEY EAST      | −43.5 | 1    | 403     | −16.2 | 1.4  | 208     | 6.3 −27.30 [−27.51, −27.09] |
| ODYSSEY HoFH      | −19.6 | 4    | 45      | 8.8   | 5.4  | 24      | 5.1 −28.40 [−30.86, −25.94] |
| ODYSSEY JAPAN     | −39.5 | 1.8  | 144     | 2.5   | 2.5  | 72      | 6.2 −42.00 [−42.65, −41.35] |
| ODYSSEY KT        | −35.9 | 3    | 97      | −2.3  | 3    | 102     | 6.1 −33.60 [−34.43, −32.77] |
| ODYSSEY LONG TERM | −29.3 | 0.7  | 1530    | −3.7  | 1    | 780     | 6.3 −25.60 [−25.68, −25.52] |
| ODYSSEY OPTIONS I | −30.8 | 4.1  | 46      | −9.7  | 4.1  | 47      | 5.7 −21.10 [−22.77, −19.43] |
| ODYSSEY OPTIONS I-2 | −23.6 | 4    | 55      | −20.2 | 4    | 53      | 5.8 −3.40 [−4.91, −1.89] |
| ODYSSEY OPTIONS I-3 | −30.8 | 4.1  | 46      | 0.2   | 3.9  | 46      | 5.7 −31.00 [−32.64, −29.36] |
| ODYSSEY OPTIONS I-4 | −23.6 | 4    | 55      | −10.6 | 4.4  | 53      | 5.7 −13.00 [−14.59, −11.41] |
| ODYSSEY OPTIONS II | −22.7 | 5.1  | 53      | −5.2  | 4.8  | 52      | 5.5 −17.50 [−19.39, −15.61] |
| ODYSSEY OPTIONS II-2 | −27.9 | 4.1  | 48      | −4    | 4.3  | 48      | 5.7 −23.90 [−25.58, −22.22] |
| ODYSSEY OPTIONS II-3 | −22.7 | 5.1  | 53      | −5.8  | 4.6  | 50      | 5.5 −16.90 [−18.77, −15.03] |
| ODYSSEY OPTIONS II-4 | −27.9 | 4.1  | 48      | −4.3  | 4.5  | 47      | 5.6 −23.60 [−25.33, −21.87] |

Total (95% CI): 16037 14567 100.0% −26.69 [−27.93, −25.44]

Heterogeneity: Tau² = 6.38; Chi² = 9787.89, df = 16 (P < 0.00001); I² = 100%
Test for overall effect: Z = 42.06 (P < 0.00001)

Favours [experimental] Favours [control]
3.3.10. Additional Analyses. In the sensitivity analysis, we addressed the influence of each trial, investigating whether omitting the studied trial would significantly alter the pooled results of the meta-analysis. When each trial was deleted one by one, the original overall estimates did not show any results of the meta-analysis. Wheneachtrialwasdeletedone omittingthestudiedtrialwouldsignificantlyalterthepooled addressed the influence of each trial, investigating whether

4. Discussion

4.1. Efficacy of PCSK9 Inhibitors. This study aimed to conduct a systematic review and meta-analysis for evaluating the effects of treatment with PCSK9 inhibitors on the blood levels of high and very-high CVD risk patients. The existing lipid-lowering drugs have a single target of intervention, and most of them only have a good modulation effect on one or several of them but cannot achieve the simultaneous modulation of multiple lipids. Our meta-analysis found that PCSK9 combination therapy resulted in beneficial and comprehensive modulation of serum LDL-C, TC, TG, ApoB, LP (a), non-HDL-C, HDL-C, and ApoA1 levels in patients with CVD high risk.

The results showed that the all-cause mortality and cardiovascular mortality were not statistically different between with or without PCSK9 inhibitors in high and very-high CVD risk patients. This might be due to the insufficient duration of clinical trials to know the effect of long-term PCSK9 inhibitor use on patient mortality. Interestingly, the addition of PCSK9 inhibitor reduced serum levels of LDL-C and TC compared with background lipid-lowering treatments without it. Accumulation of LDL and other ApoB members is known risk factors of ASCVD [37]. Recently, other meta-analysis showed that the addition of PCSK9 inhibitors to high-intensity statin therapy can significantly further reduce the expression of serum LDL-C in patients of very-high CVD risk, which is consistent to the same as our results [38, 39]. A meta-analysis study found that, for every 1 mmol/L reduction in LDL-C, the incidence of heart attacks and ischemic strokes was reduced by more than one-fifth, and there was no evidence of any threshold within the cholesterol range studied [40]. One study found that patients treated with high doses of cholesterol-lowering drugs were at increased risk of osteoporosis and cerebral hemorrhage [41, 42]. A prospective cohort study in Copenhagen that included 108,000 people confirmed a U-shaped association between LDL-C levels and all-cause mortality, with either high or low LDL-C associated with an increased risk of all-cause mortality [43]. Therefore, focusing only on LDL-C reduction in patients at high risk of CVD is one-sided, and we need to assess lipid levels comprehensively.

Despite the reductions of LDL-C with maximally tolerated statins, many people still experience dangerous cardiovascular events [44], which may be, in part, due to high serum TG level. Elevated serum levels of TGs or TG-rich lipoproteins and their remnants are all independently risk factors for CVD [45, 46]. The possible mechanisms involve the production of proinflammatory cytokines, excessive release of
Heterogeneity: $\tau^2 = 74.22$; $\chi^2 = 133878.20$, df = 19 ($P < 0.00001$)

Total (95% CI)

| Study or Subgroup          | Mean | SD  | Total | Mean | SD  | Total | Weight | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|----------------------------|------|-----|-------|------|-----|-------|--------|-------------------------------------|-------------------------------------|
| BERSO-I                   | −58  | 1.7 | 150   | 7    | 2.3 | 75    | 5.0    | −65.00 [−65.59, −64.41]             |                                    |
| BERSO-II                  | −51.4| 1.4 | 152   | 3.8  | 2   | 74    | 5.0    | −55.20 [−55.71, −54.69]             |                                    |
| FOURIER                   | −46  | 0.4925 | 12645 | 2.7  | 0.4545 | 12596 | 5.0    | −48.70 [−48.71, −48.69]             |                                    |
| ODYSSEY COMBO I           | −36.5| 23.2 | 205   | −1.1 | 21.4 | 106   | 4.6    | −35.40 [−40.57, −30.23]             |                                    |
| ODYSSEY COMBO II          | −40.7| 1.1  | 467   | −18.3| 1.5  | 240   | 5.0    | −22.40 [−22.61, −22.19]             |                                    |
| ODYSSEY EAST              | −43.5| 1    | 403   | −16.2| 1.4  | 208   | 5.0    | −27.30 [−27.51, −27.09]             |                                    |
| ODYSSEY HoFH              | −22.5| 3.7  | 45    | 7.2  | 5    | 24    | 5.0    | −29.70 [−31.97, −27.43]             |                                    |
| ODYSSEY JAPAN             | −55  | 1.2  | 144   | −1.6 | 1.7  | 72    | 5.0    | −53.40 [−53.84, −52.96]             |                                    |
| ODYSSEY KT                | −42.3| 2.4  | 97    | 4.1  | 2.3  | 102   | 5.0    | −46.40 [−47.05, −45.75]             |                                    |
| ODYSSEY LONG TERM         | −52.8| 0.7  | 1530  | 1.2  | 1    | 780   | 5.0    | −54.00 [−54.08, −53.92]             |                                    |
| ODYSSEY OPTIONS I         | −41.9| 3.4  | 46    | −3.5 | 3.3  | 47    | 5.0    | −38.40 [−39.76, −37.04]             |                                    |
| ODYSSEY OPTIONS I-2      | −33.7| 3.4  | 55    | −4.4 | 3.5  | 53    | 5.0    | −29.30 [−30.60, −28.00]             |                                    |
| ODYSSEY OPTIONS I-3      | −41.9| 3.4  | 46    | −14.3| 3.3  | 46    | 5.0    | −27.60 [−28.97, −26.23]             |                                    |
| ODYSSEY OPTIONS I-4      | −33.7| 3.4  | 55    | −10.1| 3.6  | 53    | 5.0    | −23.60 [−24.92, −22.28]             |                                    |
| ODYSSEY OPTIONS II       | −28.3| 4.3  | 53    | −9.8 | 4.1  | 52    | 5.0    | −18.50 [−20.11, −16.89]             |                                    |
| ODYSSEY OPTIONS II-2     | −36.5| 3.1  | 48    | −7.3 | 3.8  | 48    | 5.0    | −29.20 [−30.42, −27.98]             |                                    |
| ODYSSEY OPTIONS II-3     | −28.3| 4.3  | 53    | −11.2| 4.3  | 50    | 5.0    | −17.10 [−18.76, −15.44]             |                                    |
| ODYSSEY OPTIONS II-4     | −36.5| 3.1  | 48    | −9.7 | 3.1  | 47    | 5.0    | −26.80 [−28.05, −25.55]             |                                    |
| YUKAWA-1                  | −57.9| 0.9  | 146   | −2.1 | 1.3  | 73    | 5.0    | −55.80 [−56.13, −55.47]             |                                    |
| YUKAWA-2                  | −57.5| 1.1  | 224   | 6.4  | 2    | 113   | 5.0    | −63.90 [−64.30, −63.50]             |                                    |

Total (95% CI) 16612 14859 100.0% −38.44 [−42.23, −34.65]

Heterogeneity: $\tau^2 = 74.22$; $\chi^2 = 133878.20$, df = 19 ($P < 0.00001$); $I^2 = 100$

Test for overall effect: $Z = 19.87$ ($P < 0.00001$)

Figure 9: Comparison of the reduction of serum ApoB (%) from baseline between control group and experimental group.

free fatty acids, impairment of coagulation factors, and fibrinolysis [47]. In this study, we considered that the addition of PCSK9 inhibitor distinctly decreased serum TG levels in high and very-high risk CVD patients.

Lp (a) is an LDL particle with covalently linked to apolipoprotein A-I [48]. Elevated concentration of Lp (a) is mainly caused by increased production of Lp (a) particles from liver and associates with the risk of CVD [49–51]. Lp (a) accumulation promotes foam cell formation, inflammation, oxidative stress, and thrombosis at the subendothelial space [51] and then leads to a series of serious adverse cardiovascular consequences like coronary artery disease and heart failure, despite optimal LDL-C management [50]. Although conventional drug treatments, such as statins, niacin, and cholesteryl ester transfer protein, failed to reduce serum Lp (a) levels back to normal range, PCSK9 inhibitors showed satisfactory results in lowering Lp (a) [52]. Our data demonstrated that treatment with alirocumab or evolocumab reduced serum Lp (a) levels in high CVD risk patients. However, the mechanism of PCSK9 inhibitors on reducing Lp (a) is still not clear but may be through adjusting LDLR activity [53].

Recently, the Italian Federation of Cardiology suggested that non-HDL-C is more closely related to CVD than LDL-C, which could be used as a prognostic marker for atherosclerosis treatment [54]. Non-HDL-C reflects the cholesterol content of atherogenic apoB-containing lipoproteins, which includes VLDL, intermediate density lipoprotein (IDL), LDL, chylomicron remnants, and LP (a) [55]. Non-HDL-C is of an advantage over LDL-C since it includes lipoprotein with remnant cholesterol and is free from triglyceride variability [5]. Additionally, ApoB, the major structural protein in LP(a), LDL, IDL, and VLDL, is used to quantify the total atherogenic lipoproteins. It was reported that non-HDL-C and apoB are superior to LDL-C in predicting ASCVD risk [56]. A study found that PCSK9 regulates apoB secretion by affecting autophagy, which might be a mechanism of PCSK9 inhibitors in reducing apoB [57]. Our meta-analysis discovered that the intervention of PCSK9 inhibitors notably further reduced non-HDL-C and ApoB levels in patients with high CVD risk.

ApoA1 is the most abundant protein component of HDL, and reduced plasma level of ApoA1 has been implicated as a CVD risk factor [58]. Raising serum HDL-C levels pharmacologically was included in lipid-lowering strategy to prevent the adverse CVD events since the discovery of HDL-C in the 1960s [59]. Thus, HDL-C is a consistent, robust, and independent marker to predict CVD risk by both the European and American Heart Association [9]. Epidemiological and genetic studies have suggested a positive correlation between PCSK9 and HDL-C levels, possibly through reduced uptake of ApoE-containing HDL particles [60]. In this study, we indicated that the PCSK9 inhibitors memorably increased the levels of HDL and ApoA1 in high CVD risk patients.
Heterogeneity: Tau² = 1.46; Chi² = 7079.62, df = 8 (P < 0.00001);

Study or Subgroup | Mean Difference Mean Difference
|------------------|------------------|
|                  | IV, Random, 95% CI |
|                  | IV, Random, 95% CI |
| YUKAWA A-2 | 5.00 | 5.00 |
| YUKAWA A-1 | 5.00 | 5.00 |
| ODYSSEY OPTIONS II-4 | 5.00 | 5.00 |
| ODYSSEY OPTIONS II-3 | 5.00 | 5.00 |
| ODYSSEY OPTIONS II-2 | 5.00 | 5.00 |
| ODYSSEY OPTIONS II | 5.00 | 5.00 |
| ODYSSEY OPTIONS I-4 | 5.00 | 5.00 |
| ODYSSEY OPTIONS I-3 | 5.00 | 5.00 |
| ODYSSEY OPTIONS I-2 | 5.00 | 5.00 |
| ODYSSEY OPTIONS I | 5.00 | 5.00 |
| ODYSSEY LONG TERM | 5.00 | 5.00 |
| ODYSSEY OPTIONS I | 5.00 | 5.00 |
| ODYSSEY OPTIONS I-2 | 5.00 | 5.00 |
| ODYSSEY OPTIONS I-3 | 5.00 | 5.00 |
| ODYSSEY OPTIONS I-4 | 5.00 | 5.00 |
| ODYSSEY OPTIONS I | 5.00 | 5.00 |
| ODYSSEY LONG TERM | 5.00 | 5.00 |
| ODYSSEY OPTIONS I | 5.00 | 5.00 |
| ODYSSEY OPTIONS I-2 | 5.00 | 5.00 |
| ODYSSEY OPTIONS I-3 | 5.00 | 5.00 |
| ODYSSEY OPTIONS I-4 | 5.00 | 5.00 |
| ODYSSEY OPTIONS I | 5.00 | 5.00 |
| ODYSSEY LONG TERM | 5.00 | 5.00 |
| ODYSSEY OPTIONS I | 5.00 | 5.00 |
| ODYSSEY OPTIONS I-2 | 5.00 | 5.00 |
| ODYSSEY OPTIONS I-3 | 5.00 | 5.00 |
| ODYSSEY OPTIONS I-4 | 5.00 | 5.00 |
| ODYSSEY OPTIONS I | 5.00 | 5.00 |
| ODYSSEY LONG TERM | 5.00 | 5.00 |
| ODYSSEY OPTIONS I | 5.00 | 5.00 |

Test for overall effect: Z = 11.21 (P < 0.00001)

4.2. Limitations. ① The size of samples in included studies varied greatly from 69 to 27564, which led to significant heterogeneity in the results. ② Some studies did not adequately report allocation concealment, which might lead to exaggeration of curative effect. ③ Our meta-analysis was based on trials rather than on individuals. Individuals’ data allow us to perform a more rational subgroup analysis to explore sources of heterogeneity between treatment groups. ④ The dose and frequency of administration varies from study to study, and this may introduce a bias. ⑤ The patient’s background medication used different types and doses of statins, which may also have an impact on the patient’s final
lipid levels. Only a few RCTs reported changes in ApoA1 levels. Therefore, the results of this part of the data should be treated with caution.

4.3. Application Prospects. Two PCSK9 inhibitors were used in this study, including alirocumab and evolocumab. Alirocumab and evolocumab were generally well tolerated, except for adverse reactions such as flu-like symptoms, upper respiratory tract infections, and nasopharyngitis [61–63]. Therefore, PCSK9 may be a good choice for future lipid-lowering therapy. In addition, serum LP (a), TG, HDL-C, and other indicators are also related to cardiovascular events, which may also be used as alternative indicators to assess the risk and efficacy of CVD [62]. These benefits were confirmed by clinical studies, which reveals that PCSK9 inhibitors improve cardiovascular prognosis through multiple mechanisms [62]. In addition, recent studies have found that PCSK9 inhibitors may inhibit inflammation to some extent [61]. At present, PCSK9 inhibitor treatment combined with statins has received extensive attention, and a meta-analysis suggested that the addition of PCSK9 inhibitors to statins significantly promotes the regression of total atheroma volume [64]. To conclude, the future development of PCSK9 inhibitors is promising. To better understand the mechanism of PCSK9 in LDLR degradation, new molecular pathways to regulate its binding to LDLR, including PCSK9 small molecule stem RNA and PCSK9 vaccine, are to be explored. Such as inclisiran, an siRNA inhibitor of PCSK9, has the advantages of reduced LDL-C levels, good tolerability, and a low incidence of adverse events [65], which could provide new ideas for more effective PCSK9 inhibition.

5. Conclusion
This meta-analysis systematically describes the effect of addition of PCSK9 inhibitor to conventional lipid-lowering agents on regulating blood lipid levels in patients with high and very-high risk of CVD. The included results show that PCSK9 inhibitor decreased serum levels of LDL-C, TC, apoB, non-HDL-C, LP (a), TG, and increased levels of HDL-C and ApoA1 compared with conventional therapy alone.

Data Availability
The data used to support the findings of this study are included within the article.

Ethical Approval
This study does not involve human participants. Zhang and Yanrong Suo should be considered co-first authors.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

Authors’ Contributions
All authors contributed to the design and concept, performed the literature searches, wrote the manuscript and critiqued the successive versions. Yue Zhang and Yanrong Suo contributed equally to this work.

Acknowledgments
This work was supported by the National Natural Science Foundation of China (nos. 82074211 and 81804025), Tianjin Research Innovation Project for Postgraduate Students (No. 2020YJSS203), Graduate Research Innovation Project of TUTCM (No. YJSKC-20201028), and 2019 Annual Graduate Students Innovation Fund (School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; No. ZXYCXLX201904).

Supplementary Materials
Supplementary Table 1 (Table S1): PRISMA checklist. Supplementary Table 2 (Table S2): search strategy using PubMed database. Supplementary Table 3 (Table S3): inclusion criteria for patients. Supplementary Table 4 (Table S4): publication bias. Supplementary Table 5 (Table S5): sensitivity analysis. Supplementary Figure 1 (Figure S1): PRISMA flowchart of meta-analysis. Supplementary Figure 2 (Figure S2): individual bias assessment of included studies. Supplementary Figure 3 (Figure S3): summary bias assessment of included studies. Supplementary Figure 4 (Figure S4): funnel plot of the all-cause mortality. Supplementary Figure 5 (Figure S5): funnel plot of the cardiovascular mortality. (Supplementary Materials)

References
[1] G. A. Roth, G. A. Mensah, C. O. Johnson et al., “Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study,” Journal of the American College of Cardiology, vol. 76, no. 25, pp. 2982–3021, 2020.
[2] S. Francula-Zaninovic and I. A. Nola, “Management of measurable variable cardiovascular disease’ risk factors,” Current Cardiology Reviews, vol. 14, no. 3, pp. 153–163, 2018.
[3] S. M. Grundy and K. R. Feingold, “Guidelines for the management of high blood cholesterol,” In: Endotext, MDText.com, Inc., South Dartmouth, MA, USA, 2000.
[4] M. F. Piepoli, A. W. Hoes, S. Agewall et al., “European Guidelines on cardiovascular disease prevention in clinical practice,” European Heart Journal, vol. 37, no. 29, pp. 2315–2381, 2016.
[5] S. S. Carr, A. J. Hooper, D. R. Sullivan, and J. R. Burnett, “Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment,” Pathology, vol. 51, no. 2, pp. 148–154, 2019.
[6] Y. Fujihara, T. Nakamura, T. Horikoshi et al., “Remnant lipoproteins are residual risk factor for future cardiovascular events in patients with stable coronary artery disease and on-statin low-density lipoprotein cholesterol levels <70 mg/dL,” Circulation Journal, vol. 83, no. 6, pp. 1302–1308, 2019.
[7] K. L. Cho, J. Yu, T. Hayashi, S. H. Han, and K. K. Koh, “Strategies to overcome residual risk during statins era,” Circulation Journal, vol. 83, no. 10, pp. 1973–1979, 2019.
[8] F. Mach, C. Baigent, A. L. Catapano et al., “ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk,” Atherosclerosis, vol. 290, pp. 140–205, 2019.
[9] K. K. Ray, J. J. P. Kastelein, S. Matthijs Boekholt et al., “The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidemias 2011,” *European Heart Journal*, vol. 35, no. 15, pp. 960–968, 2014.

[10] A. L. Catapano, I. Graham, G. De Backer et al., “2016 ESC/EAS guidelines for the management of dyslipidaemias,” *European Heart Journal*, vol. 37, no. 39, pp. 3999–3058, 2016.

[11] Y. Wang, J. Xu, X. Zhao et al., “Association of hypertension with stroke recurrence depends on ischemic stroke subtype,” *Stroke*, vol. 44, no. 5, pp. 1232–1237, 2013.

[12] C. N. Hess, R. M. Clare, M. L. Neely et al., “Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome,” *American Heart Journal*, vol. 187, pp. 194–203, 2017.

[13] C. ¨Ozcan, A. Deleskog, A.-M. Schjerning Olsen, H. Nordahl Christensen, M. Lock Hansen, and G. Hilmar Gilsason, “Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: A Danish nationwide register-based cohort study,” *European Heart Journal—Cardiovascular Pharmacotherapy*, vol. 4, no. 1, pp. 25–35, 2018.

[14] D. I. Feldman, J. M. Pacor, R. S. Blumenthal, and K. Nasir, “Clinical trials in lipid lowering,” *Current Opinion in Cardiology*, vol. 35, no. 4, pp. 319–324, 2020.

[15] I. Pein and Z. Reiner, “Novel experimental agents for the treatment of hypercholesterolemia,” *Journal of Experimental Pharmacology*, vol. 13, pp. 91–100, 2021.

[16] K. I. Cho, I. Sakuma, I. S. Sohn, T. Hayashi, K. Shimada, and K. K. Koh, “Best treatment strategies with statins to maximize the cardiometabolic benefits,” *Circulation Journal*, vol. 82, no. 4, pp. 937–943, 2018.

[17] X. Jia, P. Lorenz, and C. M. Ballantyne, “Poststatin lipid therapeutics: A review,” *Methodist DeBakey Cardiovascular Journal*, vol. 15, no. 1, pp. 32–38, 2019.

[18] HPS2-THRIVE Collaborative Group, “HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle outcomes, and reasons for stopping study treatment,” *European Heart Journal*, vol. 34, no. 17, pp. 1279–1291, 2013.

[19] S. J. Nicholls, G. Brandrup-Wognsen, M. Palmer, and P. J. Barter, “Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER),” *The American Journal of Cardiology*, vol. 105, no. 1, pp. 69–76, 2010.

[20] M. Ogura, “PCSK9 inhibition in the management of familial hypercholesterolemia,” *Journal of Cardiology*, vol. 76, no. 2, pp. 131–142, 2020.

[21] B. J. Arsenault, N. Perrot, and R. Puri, “Therapeutic agents targeting cardiometabolic risk for preventing and treating atherosclerotic cardiovascular diseases,” *Clinical Pharmacology and Therapeutics*, vol. 104, no. 2, pp. 257–268, 2018.

[22] L. Shamseer, D. Moher, M. Clarke et al., “Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation,” *BMJ*, vol. 349, 2015.

[23] O. Olsen, P. Middleton, J. Ezzo et al., “Quality of Cochrane reviews: assessment of sample from 1998,” *BMJ*, vol. 323, no. 7317, pp. 829–832, 2001.

[24] Y. Chen, Z. Yuan, J. Lu et al., “Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: pre-specified analysis of the Chinese population from the BERSON clinical trial,” *Diabetes Obesity Metabolism*, vol. 21, 2019.

[25] M. S. Sabatine, R. P. Giugliano, A. C. Keetch et al., “Evolocumab and clinical outcomes in patients with cardiovascular disease,” *New England Journal of Medicine*, vol. 376, no. 18, pp. 1713–1722, 2017.

[26] J. G. Schwartz, P. G. Steg, M. Szarek et al., “Alirocumab and cardiovascular outcomes after acute coronary syndrome,” *New England Journal of Medicine*, vol. 379, no. 22, pp. 2097–2107, 2018.

[27] D. J. Kereiakes, J. G. Robinson, C. P. Cannon et al., “Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study,” *American Heart Journal*, vol. 169, no. 6, pp. 906–915, 2015.

[28] C. P. Cannon, B. Cariou, D. Blom et al., “Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial,” *European Heart Journal*, vol. 36, no. 19, pp. 1186–1194, 2015.

[29] D. J. Blom, M. Harada-Shiba, P. Rubba et al., “Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia,” *Journal of the American College of Cardiology*, vol. 76, no. 2, pp. 131–142, 2020.

[30] T. Teramoto, M. Kobayashi, H. Tasaki et al., “Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins—ODYSSEY Japan randomized controlled trial -,” *Circulation Journal*, vol. 80, no. 9, pp. 1980–1987, 2016.

[31] K. K. Koh, C. W. Nam, T.-H. Chao et al., “A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT),” *Journal of Clinical Lipidology*, vol. 12, no. 1, pp. 162–172, 2018.

[32] J. G. Robinson, M. Farnier, M. Kremppf et al., “Efficacy and safety of alirocumab in reducing lipids and cardiovascular events,” *New England Journal of Medicine*, vol. 372, no. 16, pp. 1489–1499, 2015.

[33] H. Bays, D. Gaudet, R. Weiss et al., “Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial,” *Journal of Clinical Endocrinology and Metabolism*, vol. 100, no. 8, pp. 3140–3148, 2015.

[34] M. Farnier, P. Jones, R. Severance et al., “Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial,” *Atherosclerosis*, vol. 244, pp. 138–146, 2016.

[35] Y. Han, J. Chen, V. K. Chopra et al., “Evolocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolaemia and on maximally tolerated statin in China, India, and Thailand,” *Journal of Clinical Lipidology*, vol. 14, no. 1, pp. 98–108, 2020.

[36] A. Hirayama, S. Yamashita, H. Inomata et al., “One-year efficacy and safety of evolocumab in Japanese patients—A pooled analysis from the open-label extension osler studies,” *Circulation Journal*, vol. 81, no. 7, pp. 1029–1035, 2017.

[37] O. S. Descamps, A. Verhaegen, F. Demeure et al., “Evolving concepts on the management of dyslipidaemia,” *Acta Clinica Belgica*, vol. 75, no. 1, pp. 80–90, 2020.
[38] K. C. Koskinas, G. C. M. Siontis, R. Piccolo et al., “Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials,” European Heart Journal, vol. 39, no. 14, pp. 1172–1180, 2018.

[39] P. P. Toth, G. G. Worthy, S. R. Gandra et al., “Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia,” Journal of American Heart Association, vol. 6, no. 10, 2017.

[40] C. Baigent, C. Baigent, L. Blackwell et al., “Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials,” Lancet (London England), vol. 376, no. 9753, pp. 1670–1681, 2010.

[41] Y. Ma, Z. Li, L. Chen, and X. Li, “Blood lipid levels, statin therapy and the risk of intracerebral hemorrhage,” Lipids in Health and Disease, vol. 15, no. 1, p. 43, 2016.

[42] M. Leutner, C. Matzhold, L. Bellach et al., “Diagnosis of osteoporosis in statin-treated patients is dose-dependent,” Annals of the Rheumatic Diseases, vol. 78, no. 12, pp. 1706–1711, 2019.

[43] C. D. L. Johannesen, A. Langsted, M. B. Mortensen, and B. G. Nordestgaard, “Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study,” BMJ, vol. 371, Article ID m4266, 2020.

[44] U. K. Sampson, S. Fazio, and M. F. Linton, “Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges,” Current Atherosclerosis Reports, vol. 14, no. 1, pp. 1–10, 2012.

[45] O. Castañer, X. Pintó, I. Subirana et al., “Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease,” Journal of the American College of Cardiology, vol. 76, no. 23, pp. 2712–2724, 2020.

[46] E. K. Duran, A. W. Aday, N. R. Cook, J. E. Buring, P. M. Ridker, and A. D. Pradhan, “Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease,” Journal of the American College of Cardiology, vol. 75, no. 17, pp. 2122–2135, 2020.

[47] Z. Reiner, “Hypertriglyceridemia and risk of coronary artery disease,” Nature Reviews Cardiology, vol. 14, no. 7, pp. 401–411, 2017.

[48] K. Schmidt, A. Noureen, F. Kronenberg, and G. Utermann, “Structure, function, and genetics of lipoprotein (a),” Journal of Lipid Research, vol. 57, no. 8, pp. 1339–1359, 2016.

[49] B. G. Nordestgaard and A. Langsted, “Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology,” Journal of Lipid Research, vol. 57, no. 11, pp. 1953–1975, 2016.

[50] A. Y. Jang, S. H. Han, I. S. Sohn, P. C. Oh, and K. K. Koh, “Lipoprotein (a) and cardiovascular diseases—revisited—,” Circulation Journal, vol. 84, no. 6, pp. 867–874, 2020.

[51] S. Tsimikas, S. Fazio, K. C. Ferdinand et al., “NHLBI working group recommendations to reduce lipoprotein (a)-mediated risk of cardiovascular disease and aortic stenosis,” Journal of the American College of Cardiology, vol. 71, no. 2, pp. 177–192, 2018.

[52] G. D. Kolovou, N. Katsiki, and D. P. Mikhailidis, “Editorial: lipoprotein (a), more than just cholesterol?” Current Medicinal Chemistry, vol. 24, no. 10, pp. 952–956, 2017.

[53] M. L. O’Donoghue, S. Fazio, R. P. Giugliano et al., “Lipoprotein (a) PCSK9 inhibition, and cardiovascular risk,” Circulation, vol. 139, no. 12, pp. 1483–1492, 2019.

[54] J. Brands and D. Müller-Wieland, “PCSK9 inhibition: new treatment options and perspectives to lower atherogenic lipoprotein particles and cardiovascular risk,” Current Atherosclerosis Reports, vol. 21, no. 10, p. 40, 2019.

[55] F. Collucchi, S. A. Di Fusco, M. Arca et al., “Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol in clinical practice: ANMCO position paper,” Journal of Cardiovascular Medicine, vol. 22, no. 8, pp. 609–617, 2021.

[56] R. Verbeek, G. K. Hovingh, and S. M. Boekholdt, “Non-high-density lipoprotein cholesterol,” Current Opinion in Lipidology, vol. 26, no. 6, pp. 502–510, 2015.

[57] M. R. Langlois and A. D. Sniderman, “Non-HDL cholesterol or apolipoprotein B: which to prefer as a target for the prevention of atherosclerotic cardiovascular disease?” Current Cardiology Reports, vol. 22, no. 8, 2020.

[58] G. Vázquez-Oliva, A. Zamora, R. Ramos et al., “Analysis of plasma albumin, vitamin D, and apolipoproteins A and B as predictive coronary risk biomarkers in the REGICOR study,” Revista Española de Cardiología, vol. 71, no. 11, pp. 910–916, 2018.

[59] H. Sun, R. M. Krauss, J. T. Chang, and B.-B. Teng, “PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction,” Journal of Lipid Research, vol. 59, no. 2, pp. 207–223, 2018.

[60] S. Kajani, S. Curley, and F. C. McGillicuddy, “Unravelling HDL-looking beyond the cholesterol surface to the quality within,” International Journal of Molecular Sciences, vol. 19, no. 7, 2018.

[61] R. P. Giugliano, T. R. Pedersen, J.-G. Park et al., “Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial,” Lancet, vol. 390, no. 10106, pp. 1962–1971, 2017.

[62] T. D. Filippatos, A. Kei, C. V. Rizos, and M. S. Eliafs, “Effects of PCSK9 inhibitors on other than low-density lipoprotein cholesterol lipid variables,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 23, no. 1, pp. 3–12, 2018.

[63] L. Strilchuk, F. Fogacci, and A. F. Cicero, “Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data,” Expert Opinion on Drug Safety, vol. 18, no. 7, pp. 611–621, 2019.

[64] W. Masson, M. Lobo, D. Siniawski et al., “Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression,” Lipids in Health and Disease, vol. 19, no. 1, 2020.

[65] Y. Banerjee, A. Pantea Stoian, A. F. Cicero et al., “Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia,” Expert Opinion on Drug Safety, vol. 21, no. 1, pp. 9–20, 2022.